Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | CVRX | Series B-2 Preferred Stock | Jun 29, 2021 | Common Stock | 1.51K | See footnote | F1, F2, F8 | |||||||
holding | CVRX | Series C-2 Preferred Stock | Jun 29, 2021 | Common Stock | 13K | See footnote | F2, F3, F8 | |||||||
holding | CVRX | Series D-2 Preferred Stock | Jun 29, 2021 | Common Stock | 14.9K | See footnote | F2, F4, F8 | |||||||
holding | CVRX | Series E-2 Preferred Stock | Jun 29, 2021 | Common Stock | 8.38K | See footnote | F2, F5, F8 | |||||||
holding | CVRX | Series F-2 Preferred Stock | Jun 29, 2021 | Common Stock | 27.3K | See footnote | F2, F6, F8 | |||||||
holding | CVRX | Series G Preferred Stock | Jun 29, 2021 | Common Stock | 636K | See footnote | F2, F7, F8 |
Id | Content |
---|---|
F1 | The shares of Series B-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series B-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
F2 | Share numbers give effect to the reverse split of each share of the Issuer's Common Stock into 0.0252857287 shares of Common Stock, effected on June 22, 2021, which will be effective for the Preferred Stock upon its conversion to Common Stock upon the closing of the Issuer's initial public offering. |
F3 | The shares of Series C-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series C-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
F4 | The shares of Series D-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series D-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
F5 | The shares of Series E-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series E-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
F6 | The shares of Series F-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series F-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
F7 | The shares of Series G Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series G Preferred Stock will automatically convert into 0.0632143218 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
F8 | The shares reported herein are held of record by Action Potential Venture Capital, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). |